Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.09% | 13.67% | 11.32% | 23.77% | 10.18% |
| Total Depreciation and Amortization | -16.74% | -19.30% | -17.08% | -19.37% | -16.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 170.47% | 45.18% | 668.78% | -78.86% | -62.37% |
| Change in Net Operating Assets | 398.96% | -33.84% | -30.69% | 145.30% | 114.04% |
| Cash from Operations | 57.20% | 13.01% | 23.29% | 35.72% | 34.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -93.88% | -93.48% |
| Total Debt Issued | -4.22% | -4.22% | -- | -- | -- |
| Total Debt Repaid | 106.73% | -- | -- | -- | -- |
| Issuance of Common Stock | -54.72% | -24.21% | -45.42% | -47.32% | -70.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -70.02% | -- | -- | -- |
| Cash from Financing | -52.65% | -40.76% | -13.64% | -30.24% | -60.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.89% | -287.28% | 91.47% | 87.06% | -184.56% |